114 related articles for article (PubMed ID: 32577751)
1. De novo evolved gene product NCYM in the pathogenesis and clinical outcome of human neuroblastomas and other cancers.
Suenaga Y; Nakatani K; Nakagawara A
Jpn J Clin Oncol; 2020 Aug; 50(8):839-846. PubMed ID: 32577751
[TBL] [Abstract][Full Text] [Related]
2. NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.
Suenaga Y; Islam SM; Alagu J; Kaneko Y; Kato M; Tanaka Y; Kawana H; Hossain S; Matsumoto D; Yamamoto M; Shoji W; Itami M; Shibata T; Nakamura Y; Ohira M; Haraguchi S; Takatori A; Nakagawara A
PLoS Genet; 2014 Jan; 10(1):e1003996. PubMed ID: 24391509
[TBL] [Abstract][Full Text] [Related]
3. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
[TBL] [Abstract][Full Text] [Related]
4. NCYM promotes calpain-mediated Myc-nick production in human MYCN-amplified neuroblastoma cells.
Shoji W; Suenaga Y; Kaneko Y; Islam SM; Alagu J; Yokoi S; Nio M; Nakagawara A
Biochem Biophys Res Commun; 2015 Jun; 461(3):501-6. PubMed ID: 25896758
[TBL] [Abstract][Full Text] [Related]
5. TAp63 represses transcription of MYCN/NCYM gene and its high levels of expression are associated with favorable outcome in neuroblastoma.
Suenaga Y; Yamamoto M; Sakuma T; Sasada M; Fukai F; Ohira M; Yamaguchi Y; Yamamoto T; Ando K; Ozaki T; Nakagawara A
Biochem Biophys Res Commun; 2019 Oct; 518(2):311-318. PubMed ID: 31427086
[TBL] [Abstract][Full Text] [Related]
6. NCYM is upregulated by lncUSMycN and modulates N-Myc expression.
Liu PY; Atmadibrata B; Mondal S; Tee AE; Liu T
Int J Oncol; 2016 Dec; 49(6):2464-2470. PubMed ID: 27748806
[TBL] [Abstract][Full Text] [Related]
7. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
[TBL] [Abstract][Full Text] [Related]
8. Secondary Structure of Human
Matsuo T; Nakatani K; Setoguchi T; Matsuo K; Tamada T; Suenaga Y
Front Oncol; 2021; 11():688852. PubMed ID: 34497756
[No Abstract] [Full Text] [Related]
9. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
10. MYCNOS functions as an antisense RNA regulating MYCN.
Vadie N; Saayman S; Lenox A; Ackley A; Clemson M; Burdach J; Hart J; Vogt PK; Morris KV
RNA Biol; 2015; 12(8):893-9. PubMed ID: 26156430
[TBL] [Abstract][Full Text] [Related]
11. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
12. Structural characterization of human
Yamamoto S; Kono F; Nakatani K; Hirose M; Horii K; Hippo Y; Tamada T; Suenaga Y; Matsuo T
Front Oncol; 2023; 13():1213678. PubMed ID: 38074684
[TBL] [Abstract][Full Text] [Related]
13. LSINCT5 activates Wnt/β-catenin signaling by interacting with NCYM to promote bladder cancer progression.
Zhu X; Li Y; Zhao S; Zhao S
Biochem Biophys Res Commun; 2018 Jul; 502(3):299-306. PubMed ID: 29772237
[TBL] [Abstract][Full Text] [Related]
14.
Mouhand A; Nakatani K; Kono F; Hippo Y; Matsuo T; Barthe P; Peters J; Suenaga Y; Tamada T; Roumestand C
Biomol NMR Assign; 2024 Jun; 18(1):65-70. PubMed ID: 38526839
[TBL] [Abstract][Full Text] [Related]
15. Silencing of the Long Noncoding RNA MYCNOS1 Suppresses Activity of MYCN-Amplified Retinoblastoma Without RB1 Mutation.
Saengwimol D; Chittavanich P; Laosillapacharoen N; Srimongkol A; Chaitankar V; Rojanaporn D; Aroonroch R; Suktitipat B; Saisawang C; Svasti S; Hongeng S; Kaewkhaw R
Invest Ophthalmol Vis Sci; 2020 Dec; 61(14):8. PubMed ID: 33270844
[TBL] [Abstract][Full Text] [Related]
16. Molecular Mechanisms of
Liu R; Shi P; Wang Z; Yuan C; Cui H
Front Oncol; 2020; 10():625332. PubMed ID: 33614505
[No Abstract] [Full Text] [Related]
17. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
18. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
Manohar CF; Salwen HR; Brodeur GM; Cohn SL
Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
[TBL] [Abstract][Full Text] [Related]
19. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
